Payer / HTA meeting · Dr. Quentin Ueda

05 Jan 2026 · In person · Dr. Quentin Ueda, Guy's and St Thomas' · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0139—

Capture insight from this engagement

Location: Guy's and St Thomas'
Therapeutic area: Nephrology
Country: United Kingdom
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Patient-reported outcomes
Treatment burden and fatigue
Steroid-sparing strategies

Scientific content used

NPH mechanism-of-action deck
Surrogate-endpoint evidence review

Questions raised

Is there any data on APRIL inhibition in FSGS?

Notes

Payer / HTA meeting with academic nephrologist at Guy's and St Thomas'. Discussed patient-reported outcomes, treatment burden and fatigue, steroid-sparing strategies.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 2
Depth of exchange: 5
Actionability: 1

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0139

Audit history (0)

All create, update and approval events for this record

No audit events in sample data